Literature DB >> 24993903

Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion.

Navid Sadri1, Julieta Barroeta, Svetlana D Pack, Zied Abdullaev, Bishwanath Chatterjee, Raghunath Puthiyaveettil, John S Brooks, Frederic G Barr, Paul J Zhang.   

Abstract

Gene rearrangements involving the Ewing sarcoma breakpoint region 1 (EWSR1) gene are seen in a broad range of sarcomas and some nonmesenchymal neoplasms. Ewing sarcoma is molecularly defined by a fusion of the EWSR1 gene (or rarely the related FUS gene) to a member of the E26 transformation-specific (ETS) family of transcription factors, frequently the EWSR1-FLI1 fusion. More recently, EWSR1 gene fusion to non-ETS family members, including the nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 2 (NFATC2) gene, has been reported in a histological variant of Ewing sarcoma. Here, we report a malignant round cell tumor of bone with an EWSR1-NFATC2 fusion gene. This report builds upon the unusual morphological and clinical presentation of bone neoplasms containing an EWSR1-NFATC2 fusion gene.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24993903      PMCID: PMC6314183          DOI: 10.1007/s00428-014-1613-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  43 in total

1.  EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.

Authors:  Tyler P Robin; Anna Smith; Erin McKinsey; Lisa Reaves; Paul Jedlicka; Heide L Ford
Journal:  Mol Cancer Res       Date:  2012-06-20       Impact factor: 5.852

2.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma.

Authors:  Siwen Hu-Lieskovan; Jeremy D Heidel; Derek W Bartlett; Mark E Davis; Timothy J Triche
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases.

Authors:  Andrew L Folpe; John R Goldblum; Brian P Rubin; Bahig M Shehata; Wendy Liu; Angelo P Dei Tos; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2005-08       Impact factor: 6.394

4.  A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor.

Authors:  Janos Sumegi; Jun Nishio; Marilu Nelson; Robert W Frayer; Deborah Perry; Julia A Bridge
Journal:  Mod Pathol       Date:  2010-11-26       Impact factor: 7.842

5.  Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion: a new tumor entity.

Authors:  Khin Thway; Andrew G Nicholson; Kay Lawson; David Gonzalez; Alexandra Rice; Bonnie Balzer; John Swansbury; Toon Min; Lisa Thompson; Kwame Adu-Poku; Anne Campbell; Cyril Fisher
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

6.  A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.

Authors:  I S Jeon; J N Davis; B S Braun; J E Sublett; M F Roussel; C T Denny; D N Shapiro
Journal:  Oncogene       Date:  1995-03-16       Impact factor: 9.867

7.  Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.

Authors:  James S Miser; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; Holcolmbe E Grier
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

8.  A benign vascular tumor with a new fusion gene: EWSR1-NFATC1 in hemangioma of the bone.

Authors:  Elsa Arbajian; Linda Magnusson; Otte Brosjö; Johan Wejde; Andrew L Folpe; Karolin H Nord; Fredrik Mertens
Journal:  Am J Surg Pathol       Date:  2013-04       Impact factor: 6.394

9.  Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy.

Authors:  Y Kaneko; K Yoshida; M Handa; Y Toyoda; H Nishihira; Y Tanaka; Y Sasaki; S Ishida; F Higashino; K Fujinaga
Journal:  Genes Chromosomes Cancer       Date:  1996-02       Impact factor: 5.006

10.  Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions.

Authors:  Lu Wang; Rohit Bhargava; Tao Zheng; Leonard Wexler; Margaret H Collins; Diane Roulston; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

View more
  7 in total

1.  Molecular Approaches to Diagnosis in Ewing Sarcoma: Fluorescence In Situ Hybridization (FISH).

Authors:  Marcel Trautmann; Wolfgang Hartmann
Journal:  Methods Mol Biol       Date:  2021

Review 2.  New fusion sarcomas: histopathology and clinical significance of selected entities.

Authors:  Markku Miettinen; Anna Felisiak-Golabek; Alejandro Luiña Contreras; John Glod; Rosandra N Kaplan; Jonathan Keith Killian; Jerzy Lasota
Journal:  Hum Pathol       Date:  2019-01-08       Impact factor: 3.466

Review 3.  EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review.

Authors:  Julio A Diaz-Perez; G Petur Nielsen; Cristina Antonescu; Martin S Taylor; Santiago A Lozano-Calderon; Andrew E Rosenberg
Journal:  Hum Pathol       Date:  2019-05-09       Impact factor: 3.466

Review 4.  Ewing sarcoma and Ewing-like tumors.

Authors:  Marta Sbaraglia; Alberto Righi; Marco Gambarotti; Angelo P Dei Tos
Journal:  Virchows Arch       Date:  2019-12-04       Impact factor: 4.064

5.  NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.

Authors:  Ken-Ichi Yoshida; Isidro Machado; Toru Motoi; Antonina Parafioriti; Maribel Lacambra; Hitoshi Ichikawa; Akira Kawai; Cristina R Antonescu; Akihiko Yoshida
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.394

6.  NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker.

Authors:  Raul Perret; Julien Escuriol; Valérie Velasco; Laetitia Mayeur; Isabelle Soubeyran; Christophe Delfour; Sébastien Aubert; Marc Polivka; Marie Karanian; Alexandra Meurgey; Sophie Le Guellec; Noelle Weingertner; Sylvia Hoeller; Jean-Michel Coindre; Frédérique Larousserie; Gaëlle Pierron; Franck Tirode; François Le Loarer
Journal:  Mod Pathol       Date:  2020-04-23       Impact factor: 7.842

7.  Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target.

Authors:  Nathan D Seligson; Richard D Maradiaga; Colin M Stets; Howard M Katzenstein; Sherri Z Millis; Alan Rogers; John L Hays; James L Chen
Journal:  NPJ Precis Oncol       Date:  2021-05-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.